Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles
Apotex Corp. is voluntarily recalling one (1) lot of Fluticasone Propionate Nasal Spray, USP, 50 mcg per spray, 120 Metered Sprays, to the consumer level. The Fluticasone Propionate Nasal Spray USP 50 mcg per spray 120 Metered Sprays has been found to contain small glass particles. The glass particles could block the actuator and impact the functionality of the pump. The issue was discovered through a customer complaint. (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 31, 2018 Category: Food Science Source Type: news
GSK Receives FDA Approval of Arnuity Ellipta for Asthma in Children From 5 Years of Age
London, UK 21 May 2018 --GSK today announced it has received approval from the US Food and Drug Administration (FDA) for the use of Arnuity Ellipta (fluticasone furoate) a once-daily inhaled corticosteroid (ICS) medicine for the maintenance... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 24, 2018 Category: Drugs & Pharmacology Source Type: news
FDA OKs Asthma Inhaler Arnuity Ellipta for Kids as Young as 5 FDA OKs Asthma Inhaler Arnuity Ellipta for Kids as Young as 5
Fluticasone furoate improves lung function in children age 5 to 11 years with asthma when used as a once-daily inhaled maintenance therapy.FDA Approvals (Source: Medscape Med Students Headlines)
Source: Medscape Med Students Headlines - May 22, 2018 Category: Universities & Medical Training Tags: Pulmonary Medicine News Alert Source Type: news
GSK ’s Arnuity Ellipta asthma therapy wins FDA nod for use in kids as young as 5 years old
GlaxoSmithKline (NYSE:GSK) won FDA approval for the use of its Arnuity Ellipta inhaler as a once-daily therapy for the maintenance treatment of asthma in children as young as five years old.
The pharmaceutical company touted its regulatory win, pointing out that the fluticasone furoate treatment is one of the only once-daily asthma therapies cleared in the U.S. for use in this age group.
Get the full story at our sister site, Drug Delivery News.
The post GSK’s Arnuity Ellipta asthma therapy wins FDA nod for use in kids as young as 5 years old appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - May 21, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Respiratory Wall Street Beat GlaxoSmithKline plc Source Type: news
Bill would limit patient access to cheaper drugs
More than 25 million Americans suffer from asthma. The condition is well-known for restricting a patient ’s airway, making it difficult to breathe and often causing coughing and wheezing. In addition to putting the squeeze on a person’s lungs, asthma is also putting pressure on patients’ wallets, as the cost of inhalers has risen to about $5,000 a year.
Doctors and patients were recently elated when a popular asthma medication went generic. Fluticasone/salmeterol is the first-ever generic asthma… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 16, 2018 Category: American Health Authors: Dr. John D. Bennett Source Type: news
Trelegy Ellipta (Fluticasone Furoate Inhalation Powder) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 10, 2018 Category: Drugs & Pharmacology Source Type: news
Dymista (Azelastine Hydrochloride and Fluticasone Propionate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 10, 2018 Category: Drugs & Pharmacology Source Type: news
Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients with COPD
24 April 2018 -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 24, 2018 Category: Drugs & Pharmacology Source Type: news
ArmonAir RespiClick (Fluticasone Propionate Multidose Dry Powder Inhaler for Oral Inhalation) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 16, 2018 Category: Drugs & Pharmacology Source Type: news
What are Indications for Allergen-specific Immunotherapy?
Discussion
Allergen-specific immunotherapy (AIT) is a disease modifying treatment for allergic disease. Sometimes referred to as desensitization, the premise is to expose the patient to small but regular amounts of a specific antigen thereby building tolerance within the patient to the allergen. AIT is often underused because of safety concerns and lack of appropriately trained health care providers and facilities to safely carry out AIT treatment. There are 4 main AIT treatments options currently:
SCIT – subcutaneous immunotherapy
Allergen is injected into the subcutaneous skin
“Shots are effective in treati...
Source: PediatricEducation.org - March 5, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
AirDuo RespiClick Inhalation Powder (Fluticasone Propionate and Salmeterol) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 10, 2018 Category: Drugs & Pharmacology Source Type: news
Novartis' Ultibro ® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide®
Novartis today announced positive results from the FLASH** study examining the safety and efficacy of directly switching chronic obstructive pulmonary disease (COPD) patients from Seretide® (salmeterol/fluticasone) 50/500 mcg to Ultibro® Breezhaler® (indacaterol/glycopyrronium) 110/50 mcg[1]. The study met the primary endpoint demonstrating that switching patients to Ultibro Breezhaler resulted in significantly improved lung function (trough FEV1)[1]. (Source: World Pharma News)
Source: World Pharma News - November 27, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
GSK submits landmark IMPACT data to US regulatory authority to support expanded label for Trelegy Ellipta
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing of a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) for the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, 'FF/UMEC/VI') for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD). (Source: World Pharma News)
Source: World Pharma News - November 23, 2017 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news
EU Approves Trelegy Ellipta for COPD EU Approves Trelegy Ellipta for COPD
The European Commission has granted marketing authorization for fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta, GlaxoSmithKline PLC and Innoviva, Inc) for the treatment of COPD.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news
fluticasone (Flonase, Flonase Allergy Relief)
Title: fluticasone (Flonase, Flonase Allergy Relief)Category: MedicationsCreated: 3/26/1998 12:00:00 AMLast Editorial Review: 11/10/2017 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - November 10, 2017 Category: Allergy & Immunology Source Type: news
